Ansbert Gadicke

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boston, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Ansbert Gadicke
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ansbert Gadicke

Form 4 holding 10%+ Owner

Harpoon Therapeutics, Inc.

Security class
Common Stock
Shares / value
6,328,095
Estimated value
$145,546,185
Report date
02 Jun 2021
Price
$23.00
Ownership
Indirect
Form 4 holding Director

Cullinan Oncology, Inc.

Security class
Common Stock
Shares / value
7,648,268
Estimated value
$95,297,419
Report date
31 Dec 2021
Price
$12.46
Ownership
Indirect
Form 4 holding Director, 10%+ Owner

Allovir, Inc.

Security class
Common Stock
Shares / value
16,674,766
Estimated value
$11,185,433
Report date
28 Jul 2022
Price
$0.6708
Ownership
By ElevateBio LLC
Form 4 holding 10%+ Owner

Repare Therapeutics Inc.

Security class
Common Shares
Shares / value
3,882,485
Estimated value
$9,415,026
Report date
12 Jul 2021
Price
$2.42
Ownership
Indirect
Form 4 holding Director

Cullinan Oncology, Inc.

Security class
Common Stock
Shares / value
595,489
Estimated value
$7,419,793
Report date
21 Dec 2021
Price
$12.46
Ownership
Direct
Form 4 holding Director, 10%+ Owner

Allovir, Inc.

Security class
Common Stock
Shares / value
30,197
Estimated value
$20,256
Report date
28 Jul 2022
Price
$0.6708
Ownership
Direct
Form 4 holding 10%+ Owner

Aktis Oncology, Inc.

Security class
Series A Redeemable Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
12 Jan 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Aktis Oncology, Inc.

Security class
Series B Redeemable Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
12 Jan 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Aktis Oncology, Inc.

Security class
Series Seed Redeemable Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
12 Jan 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Cullinan Oncology, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
21 Dec 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

TCR2 THERAPEUTICS INC.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
01 Jun 2023
Price
$1.72
Ownership
Indirect
Form 4 holding Director, 10%+ Owner

TCR2 THERAPEUTICS INC.

Security class
Common Stock Warrant (Right to Buy)
Shares / value
0
Estimated value
Report date
22 May 2023
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Ansbert Gadicke

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .